# Valsartan + Hydrochlorothiazide

## Co-Diovan 80/12.5mg

| TAH Drug Code      | [**OCOD**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCOD)                                                                                                                                                                                                                                                                                  |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 2nd-line therapy for HTN in patients whose BP is not adequately controlled by monotherapy.                                                                                                                                                                                                                                                                |
| Dosing             | HTN adult: initial therapy 1-2 tablet QD. Maximum dose: Valsartan 320 mg/hydrochlorothiazide 25 mg per day.                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Severe hepatic impairment, biliary cirrhosis & cholestasis. Anuria, severe renal impairment. Refractory hypokalemia, hyponatremia, hypercalcemia & symptomatic hyperuricemia. Pregnancy.                                                                                                                                                                  |
| Adverse Effects    | Headache, dizziness, nasopharyngitis, fatigue, upper respiratory tract infection, cough, diarrhea, arthralgia, back pain. Cardiovascular: Hypotension Gastrointestinal: Diarrhea (3%) Neurologic: Dizziness (9%), Headache (2%) Renal: Serum blood urea nitrogen raised (15% ), Serum creatinine raised (2% ) Respiratory: Cough (3%) Other: Fatigue (5%) |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                             |

